, Volume 60, Issue 12, pp 2536–2537 | Cite as

SGLT2 inhibitors and cancer: why further evidence is required



Bladder Canagliflozin Cancer Dapagliflozin Empagliflozin EMPA-REG Gastrointestinal Meta-analysis SGLT1 SGLT2 



Sodium–glucose cotransporter 2


Duality of interest

The author declares that there is no duality of interest associated with this manuscript.

Contribution statement

The author was the sole contributor to this paper.


  1. 1.
    Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia.
  2. 2.
    Zinman B, Wanner C, Lachin JM (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM 373:2117–2128CrossRefPubMedGoogle Scholar
  3. 3.
    US Food and Drug Administration (2016) FDA briefing document: Endocrine and Metabolic Drug Advisory Committee meeting. Available from Accessed 31 August 2017
  4. 4.
    Scafoglio C, Hirayama BA, Kepe V et al (2015) Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A 112:E4111–E4119CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lin H-W, Tseng C-H (2014) A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol.
  6. 6.
    Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K (2015) Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’. Diabetes Ther 6:357–375CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Medicine, Division of EndocrinologySaifee HospitalMumbaiIndia
  2. 2.Department of Medicine, Division of EndocrinologyLokmanya Tilak Municipal Medical College (LTMMC) and Lokmanya Tilak Municipal General Hospital (LTMG)MumbaiIndia
  3. 3.Endocrine ClinicMumbaiIndia

Personalised recommendations